Evolving Pharmacologic Intervention for Methamphetamine Use Disorder: A Focus on ADAPT-2
Guest: Madhukar H. Trivedi, MD
\n\n Guest: Steven Shoptaw, PhD
\n\n\n \n
Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction. These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be taken into the clinic.